BRIEF-Stavros G. Vizirgianakis Reports 5.04% Stake In Apyx Medical Corp As Of March 25- SEC Filing

Reuters04-02

April 1 (Reuters) - Apyx Medical Corp :

* STAVROS G. VIZIRGIANAKIS REPORTS 5.04% STAKE IN APYX MEDICAL CORP AS OF MARCH 25- SEC FILING

* STAVROS VIZIRGIANAKIS-BELIEVES RECENT TRADING PRICES OF APYX STOCK DO NOT ADEQUATELY REFLECT POTENTIAL VALUE OF APYX’S UNDERLYING BUSINESS, ASSETS

* STAVROS VIZIRGIANAKIS- DESIRES TO ENGAGE WITH MANAGEMENT, BOARD OF APYX TO DISCUSS NUMEROUS ISSUES FACING APYX TODAY AND IN THE NEAR FUTURE

* STAVROS VIZIRGIANAKIS- WOULD LIKE TO WORK WITH MANAGEMENT AND BOARD OF APYX TO CONDUCT STRATEGIC REVIEW OF ALL COMMERCIAL ACTIVITIES

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424771464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-02 04:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424771464","market":"us","top_or_hot":-1,"title":"BRIEF-Stavros G. Vizirgianakis Reports 5.04% Stake In Apyx Medical Corp As Of March 25- SEC Filing","media":"Reuters","content":"<html><body><p>April 1 (Reuters) - Apyx Medical Corp   :</p><p>   * STAVROS G. VIZIRGIANAKIS REPORTS 5.04% STAKE IN APYX MEDICAL CORP AS OF MARCH 25- SEC FILING</p><p>   * STAVROS VIZIRGIANAKIS-BELIEVES RECENT TRADING PRICES OF APYX STOCK DO NOT ADEQUATELY REFLECT POTENTIAL VALUE OF APYX’S UNDERLYING BUSINESS, ASSETS</p><p>   * STAVROS VIZIRGIANAKIS- DESIRES TO ENGAGE WITH MANAGEMENT, BOARD OF APYX TO DISCUSS NUMEROUS ISSUES FACING APYX TODAY AND IN THE NEAR <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a></p><p>   * STAVROS VIZIRGIANAKIS- WOULD LIKE TO WORK WITH MANAGEMENT AND BOARD OF APYX TO CONDUCT STRATEGIC REVIEW OF ALL COMMERCIAL ACTIVITIES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Stavros G. Vizirgianakis Reports 5.04% Stake In Apyx Medical Corp As Of March 25- SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Stavros G. Vizirgianakis Reports 5.04% Stake In Apyx Medical Corp As Of March 25- SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-02 04:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 1 (Reuters) - Apyx Medical Corp   :   * STAVROS G. VIZIRGIANAKIS REPORTS 5.04% STAKE IN APYX MEDICAL CORP AS OF MARCH 25- SEC FILING   * STAVROS VIZIRGIANAKIS-BELIEVES RECENT TRADING PRICES OF ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424771464","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424771464","pubTimestamp":1712004981,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 1  - Apyx Medical Corp   :   * STAVROS G. VIZIRGIANAKIS REPORTS 5.04% STAKE IN APYX MEDICAL CORP AS OF MARCH 25- SEC FILING   * STAVROS VIZIRGIANAKIS-BELIEVES RECENT TRADING PRICES OF APYX STOCK DO NOT ADEQUATELY REFLECT POTENTIAL VALUE OF APYX’S UNDERLYING BUSINESS, ASSETS   * STAVROS VIZIRGIANAKIS- DESIRES TO ENGAGE WITH MANAGEMENT, BOARD OF APYX TO DISCUSS NUMEROUS ISSUES FACING APYX TODAY AND IN THE NEAR FUTURE   * STAVROS VIZIRGIANAKIS- WOULD LIKE TO WORK WITH MANAGEMENT AND BOARD OF APYX TO CONDUCT STRATEGIC REVIEW OF ALL COMMERCIAL ACTIVITIESSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","APYX":"Apyx Medical Inc"},"translate_title":"简报——Stavros G.Vizirgianakis报告截至3月25日持有Apyx Medical Corp.5.04%的股份——提交给SEC的文件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APYX":0.9},"content_text":"April 1 (Reuters) - Apyx Medical Corp   :   * STAVROS G. VIZIRGIANAKIS REPORTS 5.04% STAKE IN APYX MEDICAL CORP AS OF MARCH 25- SEC FILING   * STAVROS VIZIRGIANAKIS-BELIEVES RECENT TRADING PRICES OF APYX STOCK DO NOT ADEQUATELY REFLECT POTENTIAL VALUE OF APYX’S UNDERLYING BUSINESS, ASSETS   * STAVROS VIZIRGIANAKIS- DESIRES TO ENGAGE WITH MANAGEMENT, BOARD OF APYX TO DISCUSS NUMEROUS ISSUES FACING APYX TODAY AND IN THE NEAR FUTURE   * STAVROS VIZIRGIANAKIS- WOULD LIKE TO WORK WITH MANAGEMENT AND BOARD OF APYX TO CONDUCT STRATEGIC REVIEW OF ALL COMMERCIAL ACTIVITIESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424771464"}